| scholarly article | Q13442814 |
| P50 | author | Olivier Boyer | Q39066473 |
| Romain Hardet | Q49740489 | ||
| Sahil Adriouch | Q56701796 | ||
| Anna Salvetti | Q61804512 | ||
| P2093 | author name string | Laurent Drouot | |
| Benjamin Chevalier | |||
| Gaëtan Riou | |||
| Laetitia Jean | |||
| Léa Dupaty | |||
| Yassine Naïmi | |||
| P2860 | cites work | Safety and efficacy of gene transfer for Leber's congenital amaurosis | Q24634724 |
| Mechanism of oral tolerance induction to therapeutic proteins | Q26866369 | ||
| Progress and prospects: immune responses to viral vectors | Q28264531 | ||
| Ecto-enzyme and signaling functions of lymphocyte CD73 | Q28268472 | ||
| Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells | Q28289781 | ||
| A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism | Q29614266 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis | Q29619339 | ||
| Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells | Q33624770 | ||
| Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice | Q33859520 | ||
| Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells | Q34137024 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells | Q34263314 | ||
| Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial | Q34311144 | ||
| Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway | Q34340613 | ||
| Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection | Q34770058 | ||
| Long-term safety and efficacy of factor IX gene therapy in hemophilia B. | Q34783922 | ||
| Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells | Q35348677 | ||
| Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. | Q35451204 | ||
| Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. | Q35591418 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Systemic protein delivery by muscle-gene transfer is limited by a local immune response | Q35847626 | ||
| Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice | Q35913697 | ||
| AAV-mediated gene transfer for treatment of hemophilia | Q36173013 | ||
| Plasmacytoid dendritic cells mediate oral tolerance | Q36534744 | ||
| Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial | Q36632019 | ||
| Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells | Q36640081 | ||
| Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 | ||
| The molecular signature of CD8+ T cells undergoing deletional tolerance | Q37187520 | ||
| Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis | Q37642861 | ||
| The complex and evolving story of T cell activation to AAV vector-encoded transgene products | Q37814051 | ||
| Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges | Q37866086 | ||
| Immune responses to AAV in clinical trials | Q37873955 | ||
| Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials | Q37943306 | ||
| Advances in recombinant adeno-associated viral vectors for gene delivery | Q38141288 | ||
| Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside | Q38195598 | ||
| Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy | Q38287263 | ||
| Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. | Q39303013 | ||
| Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D | Q39881602 | ||
| Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. | Q40485786 | ||
| Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. | Q42138485 | ||
| Priming of memory but not effector CD8 T cells by a killed bacterial vaccine | Q43921694 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| Specific oral tolerance induction with raw hen's egg in children with very severe egg allergy: a randomized controlled trial | Q45847519 | ||
| Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products | Q45868913 | ||
| Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. | Q45869966 | ||
| Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer | Q45874902 | ||
| Major role of local immune responses in antibody formation to factor IX in AAV gene transfer | Q45883516 | ||
| Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors | Q45886179 | ||
| Oral tolerance correlates with high levels of lymphocyte activity. | Q46638037 | ||
| Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance. | Q52032008 | ||
| Antigen-specific T cell activation and proliferation during oral tolerance induction. | Q52034130 | ||
| Peripheral deletion of antigen-reactive T cells in oral tolerance. | Q54167741 | ||
| Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration | Q56904883 | ||
| Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties | Q73196801 | ||
| Oral tolerance | Q83849376 | ||
| Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice | Q87544988 | ||
| Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance | Q95721788 | ||
| P433 | issue | 1 | |
| P921 | main subject | viral persistence | Q44134905 |
| P304 | page(s) | 87-95 | |
| P577 | publication date | 2015-08-12 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector | |
| P478 | volume | 24 |
| Q39394803 | Complexity of immune responses to AAV transgene products - Example of factor IX. |
| Q52721830 | Gene Therapy With Regulatory T Cells: A Beneficial Alliance. |
| Q37609101 | Ghrelin-Reactive Immunoglobulins in Conditions of Altered Appetite and Energy Balance |
| Q37256518 | Induction of Hematopoietic Microchimerism by Gene-Modified BMT Elicits Antigen-Specific B and T Cell Unresponsiveness toward Gene Therapy Products |
| Q49740101 | Oral Tolerance: Another Reason to Eat Your Veggies! |
| Q40049410 | Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer |
| Q38684383 | Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity |
| Q54402965 | The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research. |
| Q64059399 | Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity |
Search more.